“The current situation has uncovered some structural weaknesses inside the EU’s medicines offer chain and a superior dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides reported. She suggested that supply chain challenges be resolved within an EU pharmaceutical system anticipated to generally be launched by the tip of https://www.rilife.co/blog/